Elsevier

Gender Medicine

Volume 7, Issue 2, April 2010, Pages 88-108
Gender Medicine

Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies

https://doi.org/10.1016/j.genm.2010.04.006Get rights and content

Abstract

Background: Triptans are a recommended first-line treatment for moderate to severe migraine.

Objective: Using clinical trial data, we evaluated the safety and tolerability of frovatriptan as acute treatment (AT) and as short-term preventive (STP) therapy for menstrual migraine (MM).

Methods: Data from 2 Phase III AT trials (AT1: randomized, placebo controlled, 1 attack; AT2: 12-months, noncomparative, open label) and 3 Phase IIIb STP trials in MM (MMP1 and MMP2: randomized, placebo controlled, double blind, 3 perimenstrual periods; MMP3: open label, noncomparative, 12 perimenstrual periods) were analyzed. In AT1, patients treated each attack with frovatriptan 2.5 mg, sumatriptan 100 mg, or placebo. In AT2, they used frovatriptan 2.5 mg. In MMP1 and MMP2, women administered frovatriptan 2.5 mg for 6 days during the perimenstrual period, taking a loading dose of 2 or 4 tablets on day 1, followed by once-daily or BID frovatriptan 2.5 mg, respectively; in MMP3, they used BID frovatriptan 2.5 mg. In AT1, which was previously published in part, group differences in adverse events (AEs) were analyzed using the Fisher exact test, and response rates were compared using logistic regression. Post hoc analyses of sustained pain-free status with no AEs (SNAE) and sustained pain response with no AEs (SPRNAE) were performed using a 2-sample test for equality of proportions without continuity correction. For AT2 and the STP studies, data were summarized using descriptive statistics. Results of individual safety analyses for the STP studies were previously reported; the present report includes new results from a pooled analysis of MMP1 and MMP2 and a new analysis of MMP3 in which AEs were coded using Medical Dictionary for Regulatory Activities version 8.0.

Results: AT1 included 1206 patients in the safety group; AT2 included 496. In the STP studies, safety data were collected for 1487 women. In AT1 and AT2, 85.6% and 88.3%, respectively, of enrolled patients were women. Overall, AEs were generally mild to moderate (AT studies: 82.3%-90.0%; STP studies: 78.9%89.5%). In AT1, 27.3% (131/480) of frovatriptan patients, 33.4% (161/482) of sumatriptan patients, and 14.8% (36/244) of placebo patients experienced an AE considered possibly or probably related to treatment (P < 0.001 for either drug vs placebo).There were no significant differences between frovatriptan and sumatriptan in SNAE at 4 to 24 hours or in SPRNAE at 2 to 24 hours or at 4 to 24 hours. In randomized, controlled STP trials for MM, AEs were reported by 57.8% (166/287, BID) and 63.4% (210/331, once daily) of frovatriptan users versus 62.8% (216/344) of placebo recipients. There were no consistent differences in AEs reported by patients with potential cardiovascular risk or in AEs related to the use of estrogencontaining contraceptives (ECCs).

Conclusions: In randomized controlled trials and 12-month open-label studies, frovatriptan was well tolerated in these women during AT and STP therapy for MM. Subgroup analyses provide preliminary evidence of tolerability in women using ECCs and in women with comorbidities that do not contraindicate triptan use but may be suggestive of cardiovascular risk.

References (61)

  • RB Lipton et al.

    Migraine prevalence, disease burden, and the need for preventive therapy

    Neurology

    (2007)
  • TJ Steiner et al.

    The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity

    Cephalalgia

    (2003)
  • LJ Stovner et al.

    Epidemiology of headache in Europe

    Eur j Neurol

    (2006)
  • WF Stewart et al.

    Cumulative lifetime migraine incidence in women and men

    Cephalalgia

    (2008)
  • M Leonardi et al.

    The global burden of migraine: Measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF)

    J Headache Pain

    (2005)
  • The International Classification of Headache Disorders: 2nd Edition

    Cephalalgia

    (2004)
  • F Granella et al.

    Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres

    Cephalalgia

    (2004)
  • EA MacGregor et al.

    Prevalence of migraine on each day of the natural menstrual cycle

    Neurology

    (2004)
  • A MaassenVanDenBrink et al.

    Coronary side-effect potential of current and prospective antimigraine drugs

    Circulation

    (1998)
  • SD Silberstein

    Practice parameter: Evidence-based guidelines for migraine headache (an evidencebased review): Report of the Quality Standards Subcommittee for the American Academy of Neurology

    Neurology

    (2000)
  • P Tfelt-Hansen et al.

    Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy

    Drugs

    (2000)
  • A MaassenVanDenBrink et al.

    Coronary vasoconstrictor potential of triptans: A review of in vitro pharmacologic data

    Headache

    (2004)
  • KM Kelly

    Cardiac arrest following use of sumatriptan

    Neurology

    (1995)
  • P O'Connor et al.

    Oral sumatriptanassociated transmural myocardial infarction

    Neurology

    (1995)
  • JE Jayamaha et al.

    Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan

    Intensive Care Med

    (1995)
  • Frova (frovatriptan succinate) [prescribing information]

    (2007)
  • Zomig, Zomig-ZMT (zolmitriptan) [prescribing information]

    (2007)
  • Amerge (naratriptan hydrochloride) [prescribing information]

    (2007)
  • T Kurth et al.

    Migraine frequency and risk of cardiovascular disease in women

    Neurology

    (2009)
  • A Wade et al.

    Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebocontrolled, two-period crossover, single-centre study in healthy female volunteers

    Clin Drug Investig

    (2009)
  • FD Sheftell et al.

    Patterns of use of triptans and reasons for switching them in a tertiary care migraine population

    Headache

    (2004)
  • R Lipton et al.

    Acute migraine therapy: Do doctors know what migraine patients want from therapy?

    Headache

    (1999)
  • MD Ferrari et al.

    Triptans (serotonin,5-HT1 B/1 Dagonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials

    Cephalalgia

    (2002)
  • M Bigal et al.

    Satisfaction with current migraine therapy: Experience from 3 centers in US and Sweden

    Headache

    (2007)
  • J Goldstein et al.

    Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan

    Headache

    (2006)
  • R Ryan et al.

    Clinical efficacy of frovatriptan: Placebo-controlled studies

    Headache

    (2002)
  • G Geraud et al.

    Tolerability and safety of frovatriptan with short- and longterm use for treatment of migraine and in compari son with sumatriptan

    Headache

    (2002)
  • P Buchan et al.

    Clinical pharmacokinetics of frovatriptan

    Headache

    (2002)
  • G Geraud et al.

    Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans

    Headache

    (2003)
  • AA Parsons et al.

    Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coro nary arteries

    J Cardiovasc Pharmacol

    (1998)
  • Cited by (0)

    View full text